NSI-189 vs PE-22-28
Side-by-side comparison of NSI-189 and PE-22-28: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
NSI-189
PE-22-28
NSI-189
NSI-189 is a novel synthetic compound developed by Neuralstem Inc. that stimulates neurogenesis in the human hippocampus. Phase 2 trials for major depressive disorder showed improvements in subjective cognitive function,…
Lowest listed price: $84.99 across 1 listing
Full NSI-189 profilePE-22-28
PE-22-28 is a synthetic seven-amino-acid peptide (sequence PAGASRLLLLTGEIDLP derivative, commonly truncated to PE-22-28 as shorthand for "position 22-28" within the parent humanin-family sequence) that was designed as an…
Lowest listed price: $54.99 across 1 listing
Full PE-22-28 profileSide-by-side comparison
| Attribute | NSI-189 | PE-22-28 |
|---|---|---|
| Category | Nootropics | Nootropics |
| Research Stage | Preclinical | Preclinical |
| Mechanism of Action | NSI-189 stimulates proliferation and differentiation of human hippocampal neural stem cells through a mechanism distinct from BDNF or classical antidepressants. Rodent studies show a 20% increase in hippocampal volume after 6 weeks of treatment. It is not a… | PE-22-28 is a synthetic 7-amino-acid peptide (sequence GVSWGLR) and a shortened analog of spadin. Its proposed mechanism is inhibition of the TREK-1 (TWIK-related K+) channel, a two-pore-domain potassium channel (K2P2.1 / KCNK2) implicated in mood regulation.… |
| Half-Life | — | Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242]. |
| Typical Dose Range | — | 250-2000 mcg subcutaneous per dose (empirical research-chemical community range; no clinically validated human dose exists; effective preclinical rodent doses were far lower, ~3 mcg/kg). |
| Dosing Frequency | — | Once daily or every other day (research-chemical community protocols; no validated clinical dosing schedule). |
| Administration | — | — |
| Side Effects | Mild GI discomfort, injection site reaction (if injected), headache. Very well-tolerated. Rare: anxiety or insomnia at high doses. | No human side-effect data exist for PE-22-28 because it has never been tested in people. What can be said comes from rodent studies of PE-22-28, spadin and their analogs, plus general considerations for injected research peptides. In the preclinical work, the… |
| Molecular Weight | 313.36 g/mol | 773.9 g/mol |
| Common Vial Sizes | — | — |
Price tracking
Price tracking
NSI-189: potential benefits
- Increased hippocampal neurogenesis
- Antidepressant effects
- Enhanced synaptic plasticity
- Improved cognitive function
- Long-lasting mood improvement
- Potential PTSD treatment
PE-22-28: potential benefits
- Antidepressant-like effects in rodent models of depression (preclinical only)
- Potent, selective inhibition of the TREK-1 (K2P2.1) potassium channel (IC50 ~0.12 nM)
- Rapid-onset (~4-day) antidepressant profile in animals, unlike the multi-week lag of SSRIs
- Increased hippocampal neurogenesis in mice
- Increased cortical synaptogenesis (PSD-95) and BDNF expression in preclinical studies
- No human-validated benefits; not approved for any use (research use only)
Frequently asked
What's the difference between NSI-189 and PE-22-28?
NSI-189 is a nootropics that nsi-189 stimulates proliferation and differentiation of human hippocampal neural stem cells through a mechanism distinct from bdnf or classical antidepressants. rodent studies show…. PE-22-28 is a nootropics that pe-22-28 is a synthetic 7-amino-acid peptide (sequence gvswglr) and a shortened analog of spadin. its proposed mechanism is inhibition of the trek-1 (twik-related k+) channel, a…. The two differ in mechanism, half-life (not reported vs Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242].), and typical dose range.
Which has the longer half-life, NSI-189 or PE-22-28?
NSI-189 has a half-life of not reported. PE-22-28 has a half-life of Not characterized in humans. As a small 7-amino-acid peptide a short plasma half-life is expected; in mice the parent peptide spadin lost antidepressant activity by about 7 hours after a single dose, while modified analogs (e.g., G/A-PE 22-28) extended the behavioral effect to roughly 21-23 hours [PMID:28955242].. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, NSI-189 or PE-22-28?
Lowest listed price on BodyHackGuide: NSI-189 from $84.99, PE-22-28 from $54.99. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack NSI-189 and PE-22-28?
Stacking depends on mechanism overlap, safety profile, and goals. NSI-189 and PE-22-28 should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy NSI-189 or PE-22-28
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. Every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.